Milk kefir therapy improves the skeletal response to resistance exercise in rats submitted to glucocorticoid-induced osteoporosis

Vasconcelos, Raquel Felipe de; Costa, Vanessa Polina Pereira; Araújo, Bruno Martins; Maia, Thays Allane Cordeiro; Dias, Romero; Vasconcelos, Lorena; Silveira, Helson; Carneiro, Bárbara; Thiers, Diego; Costa, Fábio Wildson Gurgel; Kurita, Lúcio; Ayala, A. P.; Leitão, Renata F. C.; Pereira, Karuza Maria Alves; Gondim, Delane Viana; Góes, Paula

doi:10.1016/j.exger.2022.111921

Cited by 5 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concomitantly, KP treatment improved BMD and microarchitecture in trabecular ( Figure 4 ) and cortical bones ( Figure 5 ) with an increase in the circulating bone formation marker P1NP and a reduction in the resorption marker CTX1 ( Figure 6 ), which showed that bone remodeling favored bone formation in KP-treated ApoE −/− mice. In fact, KPs have repeatedly demonstrated bone-protective benefits in our earlier animal models of osteoporosis caused by estrogen depletion ( Chen et al, 2015 ; Tu et al, 2020 ), hemophilia ( Yen et al, 2022 ), and vitamin C insufficiency ( Chang et al, 2022 ), and rats with glucocorticoid-induced osteoporosis ( de Vasconcelos et al, 2022 ). We recently demonstrated that KPs promoted osteoblastic differentiation and bone mineralization while inhibiting RANKL-induced osteoclastic differentiation and bone resorption in vitro ( Chang et al, 2022 ), and treatments with KPs eventually lowered the circulating RANKL/OPG ratio in vivo ( Chang et al, 2022 ; Yen et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Kefir peptides attenuate atherosclerotic vascular calcification and osteoporosis in atherogenic diet-fed ApoE−/− knockout mice

Chang

Cheng

Fan

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Aims: Vascular calcification (VC) and osteoporosis were previously considered two distinct diseases. However, current understanding indicates that they share common pathogenetic mechanisms. The available medicines for treating VC and osteoporosis are limited. We previously demonstrated that kefir peptides (KPs) alleviated atherosclerosis in high-fat diet (HFD)-induced apolipoprotein E knockout (ApoE−/−) mice. The present study further addressed the preventive effects of KPs on VC and osteoporosis in ApoE−/− mice fed a high-cholesterol atherogenic diet (AD).Main methods: Seven-week-old ApoE−/− and wild-type C57BL/6 mice were randomly divided into five groups (n = 6). The development of VC and osteoporosis was evaluated after AD feeding for 13 weeks in KP-treated ApoE−/− mice and compared to C57BL/6 and ApoE−/− mice fed a standard chow diet (CD).Key findings: The results indicated that KP-treated ApoE−/− mice exhibited lower serum total cholesterol, oxidized low-density lipoprotein (ox-LDL), malondialdehyde (MDA) levels, and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatine kinase (CK) activities, which suggested that KPs prevented hyperlipidemia and possible damages to the liver and muscle in ApoE−/− mice. KPs reduced serum tumor necrosis factor-α (TNF-α) and the local expression of TNF-α, IL-1β, and macrophage-specific CD68 markers in aortic tissues, which suggested that KPs inhibited inflammatory responses in AD-fed ApoE−/− mice. KPs reduced the deposition of lipid, collagen, and calcium minerals in the aortic roots of AD-fed ApoE−/− mice, which suggested that KPs inhibited the calcific progression of atherosclerotic plaques. KPs exerted osteoprotective effects in AD-fed ApoE−/− mice, which was evidenced by lower levels of the bone resorption marker CTX-1 and higher levels of the bone formation marker P1NP. KPs improved cortical bone mineral density and bone volume and reduced trabecular bone loss in femurs.Significance: The present data suggested that KPs attenuated VC and osteoporosis by reducing oxidative stress and inflammatory responses in AD-fed ApoE−/− mice. Our findings contribute to the application of KPs as preventive medicines for the treatment of hyperlipidemia-induced vascular and bone degeneration.

show abstract

Section: Discussionmentioning

confidence: 99%

Kefir peptides attenuate atherosclerotic vascular calcification and osteoporosis in atherogenic diet-fed ApoE−/− knockout mice

Chang

Cheng

Fan

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…The bioconversion of whey by kefir lactic acid bacteria (LAB) may be effective in reducing obesity and obesity-related diseases [24]. Besides, several authors [25][26][27] report that milk kefir enhances bone microarchitecture and metabolism, has osteoprotective effects and can be used as a nutritional supplement to accelerate fracture healing. The antimicrobial activity of kefir microorganisms derives from the microorganisms' capacity to adhere to the intestinal epithelium, preventing the adhesion of pathogens, among other properties.…”

Section: Introductionmentioning

confidence: 99%

Application of Ultrafiltration To Produce Sheep’s and Goat’s Whey Based Synbiotic Kefir Products

Pires¹,

Tan²,

Gomes³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Linking the relation between gut microbiota and glucocorticoid-induced osteoporosis

et al. 2023

View full text Add to dashboard Cite

Milk kefir therapy improves the skeletal response to resistance exercise in rats submitted to glucocorticoid-induced osteoporosis

Cited by 5 publications

References 58 publications

Kefir peptides attenuate atherosclerotic vascular calcification and osteoporosis in atherogenic diet-fed ApoE−/− knockout mice

Kefir peptides attenuate atherosclerotic vascular calcification and osteoporosis in atherogenic diet-fed ApoE−/− knockout mice

Application of Ultrafiltration To Produce Sheep’s and Goat’s Whey Based Synbiotic Kefir Products

Linking the relation between gut microbiota and glucocorticoid-induced osteoporosis

Contact Info

Product

Resources

About